Till sidans topp

Sidansvarig: Webbredaktion
Sidan uppdaterades: 2012-09-11 15:12

Tipsa en vän
Utskriftsversion

Secondary hyperparathyroi… - Göteborgs universitet Till startsida
Webbkarta
Till innehåll Läs mer om hur kakor används på gu.se

Secondary hyperparathyroidism but stable bone-mineral density in patients with chronic myeloid leukemia treated with imatinib.

Artikel i vetenskaplig tidskrift
Författare Sofia Jönsson
Therese Standal
Bob Olsson
Dan Mellström
Hans Wadenvik
Publicerad i American journal of hematology
Volym 87
Nummer/häfte 5
Sidor 550-2
ISSN 1096-8652
Publiceringsår 2012
Publicerad vid Institutionen för medicin, avdelningen för invärtesmedicin och klinisk nutrition
Sidor 550-2
Språk en
Ämnesord Aged, Alkaline Phosphatase, blood, Antineoplastic Agents, adverse effects, pharmacology, therapeutic use, Biological Markers, Bone Density, Calcium, blood, Collagen Type I, blood, Female, Humans, Hyperparathyroidism, Secondary, chemically induced, Leukemia, Myelogenous, Chronic, BCR-ABL Positive, blood, complications, drug therapy, Magnesium, blood, Male, Menopause, Middle Aged, Osteocalcin, blood, Parathyroid Hormone, blood, Peptides, blood, Piperazines, adverse effects, pharmacology, therapeutic use, Protein Kinase Inhibitors, adverse effects, pharmacology, therapeutic use, Pyrimidines, adverse effects, pharmacology, therapeutic use, Smoking, blood
Ämneskategorier Hematologi

Sammanfattning

Imatinib is currently the standard treatment for chronic myeloid leukemia(CML). Previous studies have shown that imatinib affects bone metabolism in CML patients. However, these effects are not well-studied prospectively. The authors studied bone-mineral density (BMD) and bone metabolism in 17 CML patients and matched controls in 2007 and now repeated the analyses prospectively in 2011. All CML patients were in complete cytogenetic remission during this 4-year period and treated with 400 mg imatinib q.d. (n 5 15) or 600 mg imatinib q.d. (n 5 2). Mean treatment duration was 102 months (range 69–129) in 2011. The authors found that serum levels of parathyroid hormone increased significantly in the patients between 2007 and 2011, and seven out of 17 patients had secondary hyperparathyroidism in 2011. However, the mean areal and volumetric BMDs were stable in the CML patients over the 4-year-observation period. Moreover, the CML patients had significantly higher volumetric BMD in the cortical compartment when compared with controls in 2011 and 2007. Thus, despite a high incidence of secondary hyperparathyroidism,there were no signs of osteoporosis or osteomalacia in imatinib-treated CML patients as suggested earlier.

Sidansvarig: Webbredaktion|Sidan uppdaterades: 2012-09-11
Dela:

På Göteborgs universitet använder vi kakor (cookies) för att webbplatsen ska fungera på ett bra sätt för dig. Genom att surfa vidare godkänner du att vi använder kakor.  Vad är kakor?